NCT03594045 - Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2018

Primary Completion Date

October 30, 2019

Study Completion Date

October 30, 2019

Conditions

Heparin-induced ThrombocytopeniaHeparin-induced Thrombocytopenia and Thrombosis

Interventions

DRUG

Apixaban

Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.

Trial Locations (3)

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Brigham and Women Hospital, Boston